Despite promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable resistance from managed care entities. The insurers are frequently erecting obstacles to reimbursement, including significant price criteria and PA that hinder user access. Industry suggest that such